Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist

Luteinizing hormone-releasing hormone (LHRH) agonist therapy is commonly used as a form of hormonal ablative therapy in patients with advanced prostate cancer. It is important to administer LHRH agonist every four weeks. Any delay of more than two weeks is associated with the risk of disease flare....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urology (Ridgewood, N.J.) N.J.), 1993-11, Vol.42 (5), p.533-535
Hauptverfasser:	Shaheen, J.Anthony, Amin, Mohammad, Harty, James I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Chemotherapy Follow-Up Studies Goserelin - administration & dosage Goserelin - therapeutic use Humans Male Medical sciences Middle Aged Patient Acceptance of Health Care Pharmacology. Drug treatments Prostatic Neoplasms - drug therapy Receptors, LHRH - drug effects Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!